Evaluation of Biological Markers of Mesenteric Ischemia During an Ultra-trail

Overview

To assess the evolution of biological markers of mesenteric ischemia during ultratrail.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 30, 2015

Detailed Description

During physical exercise, increased sympathetic nervous system activity redistributes blood flow from splanchnic organs to working muscles. With prolonged duration and / or intensity, the splanchnic blood flow can be reduced by 80% or more. A severely reduced of splanchnic blood flow can frequently cause gastrointestinal ischemia. This ischemia associated with reduced vagal activity probably results in changes in motility and absorption. High symptoms are reported in 40% of runners with reflux and heartburn in 15-20% of runners. The low symptoms have an incidence of about 70% in the long runs type ultra-trail. Biological markers such as I-FABP have been shown to be useful in the diagnosis of mesenteric ischemia.

Interventions

  • Biological: Blood analysis
    • Blood test of biological markers of mesenteric ischemia

Arms, Groups and Cohorts

  • Runners
    • To assess the evolution of biological markers of mesenteric ischemia during ultratrail.

Clinical Trial Outcome Measures

Primary Measures

  • Assess biological markers of mesenteric ischemia (IFABP)
    • Time Frame: at day 1
    • during ultratrail.

Secondary Measures

  • Relationship between digestive symptoms and biological markers (IFABP).
    • Time Frame: at day 1

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy Voluntary Subject – Age > 18 years – Written consent – Subject affiliated to Social Security – Medical certificate (mandatory to take part in the ultra-trail) Exclusion Criteria:

  • Refusal to participate – Subject with legal protection (guardianship, trusteeship)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University Hospital, Clermont-Ferrand
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Sébastien PERBET, Principal Investigator, CHU de Clermont-Ferrand

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.